Biofrontera Inc. Common Stock is a biopharmaceutical company that focuses on the development and commercialization of dermatological drugs and medical cosmetics. The company’s flagship product is Ameluz, which is used to treat actinic keratosis. With a strong focus on research and innovation, Biofrontera is poised for growth in the dermatology market.
Notification